NETDA's biomedicine firm receives EU certificate
Nantong Egens Biotechnology Co Ltd acquires the EC certificate for its COVID-19 antigen detection product. [Photo provided to NETDA]
Recently, the COVID-19 antigen detection kit independently developed by Nantong Egens Biotechnology Co Ltd passed the European clinical examination, strict technical examination and has successfully obtained the EC certificate.
The EC certificate of conformity is valid in all EU countries.
Established in 1999 in the Nantong Economic and Technological Development Area, or NETDA, which is located in Nantong city in East China's Jiangsu province, Egens Biotechnology has been leading the industry in family reproductive health detection, drug detection and drug abuse, infectious disease detection, tumor diagnosis and other fields.
In 2020, Egens Biotechnology invested 500 million yuan ($74.56 million) to set up a subsidiary corporation in NETDA to build a research, development and production base for COVID-19 testing reagents.
Thanks to the comprehensive services and high-quality business environment of NETDA, Egens Biotechnology has invested nearly 600 million yuan in the area since 2021, and has successively set up a series of subsidiaries.
In addition, Egens Biotechnology has also obtained EC certificates for a number of monkeypox virus detection kits and drug abuse rapid detection kits.